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Prostate cancer is the most common cancer in men in the United States, and it is the second leading cause of cancer-related death
in Americanmen. The androgen receptor (AR), a receptor of nuclear family and a transcription factor, is the most important target
in this disease. While most eﬀorts in the clinic are currently directed at lowering levels of androgens that activate AR, resistance to
androgen deprivation eventually develops. Most prostate cancer deaths are attributable to this castration-resistant form of prostate
cancer (CRPC). Recent work has shed light on the importance of epigenetic events including facilitation of AR signaling by histone-
modifying enzymes, posttranslational modifications of AR such as sumoylation. Herein, we provide an overview of the structure
of human AR and its key structural domains that can be used as targets to develop novel antiandrogens. We also summarize recent
findings about the antiandrogens and the epigenetic factors that modulate the action of AR.
1. Introduction
Prostate cancer (PC) is the second most prevalent cause of
death in men in the USA and Europe. The dependence of PC
on androgens has been recognized for more than 7 decades.
Medical and surgical androgen deprivation therapy (ADT)
has been a standard palliative therapy for metastatic PC.
However, an estimated 217,730 new cases and 32,050 PC-
related deaths in the USA alone in 2010 despite ADT [1]
make the need for finding new targets and novel therapies an
absolute priority.
Androgen, the male steroid hormone, is responsible for
male sexual diﬀerentiation and development, as well as the
maintenance and support of sexual tissues in the adult.
Moreover, androgens are important for the development and
progression of age-associated pathologies in men, including
benign prostatic hyperplasia and prostate cancer (PC).
Androgen action is exerted through the androgen receptor
(AR), a 110-kDa member of the steroid receptor family of
transcription factors [2]. The physiological ligands for the
AR are testosterone and dihydrotestosterone (DHT). The
later has at least 10-fold stronger binding aﬃnity.
The most commonly used therapies in metastatic pros-
tate cancer involve androgen deprivation through medical
(LHRH agonists), surgical castration, or disruption of andro-
gen binding to AR [3]. Such treatments are temporarily
eﬀective, but, over time, most prostate cancers evolve into a
castration-resistant state [4, 5]. Resistance mechanisms
include AR, gene mutation or amplification, ligand indepen-
dent activation of AR and persistent intraprostatic androgens
[6–8]. Importantly, even in castration resistant prostate
cancer (CRPC), AR still plays an essential role in can-
cer progression [6]. Recent work indicates that epigenetic
enzymes are important coactivators of AR andmay represent
targets to influence AR stability and activity, thus providing
new therapeutic opportunities to overcome mechanisms of
resistance.
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Histone-deacetylating and DNA-methylating enzymes,
act to modify certain histone and nonhistone proteins such
as the chaperone protein HSP90, which leads to enhanced
protein stability of client proteins including AR [9–11]. Due
to the central role of AR in all phases of prostate cancer, mod-
ulating AR protein stability or AR cofactor activity represents
an eﬀective strategy to overcome most of the mechanisms
of resistance and may have therapeutic implications in this
disease.
This paper discusses the structure of androgen receptor,
current antiandrogen therapies, the emerging therapies that
target the AR, epigenetic modulation of AR, and therapies
targeting epigenetic modulation.
2. Androgen Receptor (AR)
AR is a nuclear hormone receptor, which is activated by
binding of androgen ligands. Upon androgen binding, AR
dissociates from the cytoplasmic chaperone protein HSP90,
self-dimerizes and translocates to the nucleus. AR then
binds to consensus sequences in the genome called AREs
(androgen response elements) to activate transcription of its
target genes, which is essential for prostate development and
maintenance [12].
Structure of AR. The AR shares an overall modular organiza-
tion which has an N-terminal domain (NTD) containing the
activation function (AF)-1, a central DNA binding domain
(DBD), a short hinge region, and a COOH terminal domain
(CTD), which contains both the AR ligand-binding domain
(LBD) and AF-2 coactivator binding surface (Figure 1) [13].
The three-dimensional structures of peptides representing
the LBD and AF-2 folds of the AR have been determined by
X-ray crystallography. The three-dimensional structure of a
peptide representing the AR DBD has also been determined
[14, 15]. The AR NTD, on the contrary, is unstructured in
solution, and thus it has been diﬃcult to predict its structure
accurately. Nevertheless, several critical functional domains
have been described and characterized within the AR NTD.
Posttranslational modifications of the AR, including phos-
phorylation, acetylation, ubiquitylation, and sumoylation,
add additional layers of regulation and are likely to influence
the structure and function of these domains [16] (Figure 1).
2.1. AR C-Terminal Domain (CTD). The role of the AR
CTD is of particular importance for PC, because the current
androgen ablation therapies target this domain of the
AR. This prevents both AR nuclear translocation and the
exposure of AF-2. Antiandrogens such as bicalutamide bind
the LBD, block the activity of AF-2 [12], and cause AR
to recruit corepressor molecules such as nuclear receptor
corepressor (NCoR) to the promoters of AR-regulated genes
[17, 18]. This inhibits AR activity and thus halts the growth
and survival of androgen-dependent PC cells. Binding of
ligand to the AR LBD causes a conformational change in the
AR CTD, which induces formation of the AF-2 coactivator
binding surface. The AF-2 surface serves as a docking site
for LxxLL motifs present in transcriptional coactivators and
NTD DBD
AF-1
LBD CTE
CTD
AF-2Hinge
Figure 1: Schematic representation of the structure of human
androgen receptor NTD: N-terminal domain, DBD: DNA-binding
domain, LBD: ligand-binding domain, CTE: C-terminal extension,
CTD: C-terminal domain, AF-1: activation function-1, AF-2:
activation function-2.
corepressors. Unlike the LBD of other nuclear receptors, the
AR LBD displays very weak ligand-dependent transcriptional
activity unless stimulated by p160 coactivators such as steroid
receptor coactivator (SRC)-1 or SRC-2 [19, 20]. This is in
absolute contrast to the potent inherent transcriptional ac-
tivity of an isolated AR NTD fragment [20–22].
The transcriptional activity of most steroid hormone
receptors is predominantly through the activation function
AF-2 region in the LBD. However, in the AR, it is the AF-1
region in the NTD that contributes most to the transcrip-
tional activity [23]. AR LBD functions independently of the
NTD and can still bind ligand even if the AF-1 region is
deleted or mutated; however, AF-1 region in the NTD is an
absolute requirement for the transcriptional activity to take
place.
2.2. AR N-Terminal Domain (NTD). The AR NTD is highly
flexible and displays intrinsic disorder in solution, which has
hampered elucidation of its three-dimensional structure [13,
24]. In other words, it represents a rigid secondary structure
which is either exposed or concealed depending on various
factors such as androgen levels, cell type, posttranslational
modifications, and presence or absence of transcriptional
modulators. The AR NTD accounts for more than 60%
of the AR protein. Therefore, understanding the dynamic
nature of the AR NTD is critically important. It functions
as a potent transcriptional activator independent of the
CTD. The AF-1 domain serves as a binding site for the
transcriptional repressors- N-CoR (nuclear corepressor) and
SMRT (silencing mediator of retinoic acid and thyroid
hormone receptor). Sumoylation (SUMO-small ubiquitin-
like modifier) is a type of posttranslational modification.
Sumoylation by SUMO-1 protein requires two discrete lysine
residues—K386 and K520. These modifications inhibit AR
activity through a mechanism that may involve SMRT’s
interaction with the AR NTD [25, 26]. To sum up, the AR
NTD plays a multifunctional and dynamic role in regulating
AR activity and is a very important target.
2.3. AR-DBD. The AR DBD/hinge region plays important
roles in mediating AR nuclear localization, receptor dimer-
ization, and DNA binding. All the hormone receptor DBDs
are highly conserved. It consists of two zinc-fingers and a
loosely structured carboxy-terminal extension (CTE) [27]. It
is responsible for dimerization of AR and tight binding of AR
dimer to the DNA.
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Ligand binding induces a conformational change in AR
inducing phosphorylation [28], nuclear translocation [29],
and dimerization. As described above, AR dimmer then
binds to androgen response elements (AREs) located in the
regulatory regions of target genes [30] and actively recruits
essential cofactors and assembles the transcriptional machin-
ery required to regulate the expression of androgen-regulated
genes [31, 32]. A critical component of this signaling axis is
the ability of the receptor to undergo dimerization.
2.4. AR Dimerization. Dimerization mediated through the
AR-DBD is an absolute requirement for AR signaling. By
assembling on DNA targets, the AR homodimer specifically
binds DNA to regulate the expression of AR target genes.
Whereas the N/C (NTD/CTD) interaction provides a poten-
tial mechanism for regulation of AR activity, further studies
are necessary to determine the precise role and contribution
of each model of AR N/C interaction to AR signaling.
Based on evidence that AR-LBD dimerization can occur, it is
likely that this interaction also contributes to AR signaling.
Centenera et al. showed that interaction of multiple AR
domains is required for optimal AR-mediated signaling [33].
3. Therapies Targeting Androgen Signaling
Currently, all conventional therapy has been focused on
androgen-dependent activation of the AR through its C-
terminal LBD. A schematic of their mechanism of action is
shown in (Figure 2).
Below is a summary of the currently used therapies tar-
geting androgen signaling.
3.1. Androgen Deprivation Therapy (ADT)—Castration. Sev-
eral studies have attempted to surgically or pharmaco-
logically target androgenic stimulation. The goal of these
interventions is to slow disease progression, and to treat the
disease. Surgical castration completely eliminates testosterone
production by the testes, whereas administration of an
LHRH agonist (medical castration) generates castrate levels
of serum testosterone (<20 or <50 ng/dL, resp.) by having
a negative hormonal feedback on the hypothalamus [34].
There was no statistically significant diﬀerence in disease-
free or overall survival for metastatic patients treated with
either of the these testosterone-lowering treatments [35].
Castration was associated with a number of adverse eﬀects
like hot flashes, loss of libido, and decreased quality of life.
3.2. CYP17 Inhibitors. Blocking the in situ production of
androgens by inhibition of CYP 17 enzyme is a critical key
in the treatment of patients with advanced and/or metastatic
prostate cancer. The following section describes the currently
used CYP17 inhibitors and relevant data about them in
clinical trials. The structures of ketoconazole, abiraterone
acetate and VN/124-1 (TOK-001) are presented in Figure 3.
3.2.1. Ketoconazole. Ketoconazole is a broad spectrum anti-
fungal agent that has been extensively used oﬀ-label as sec-
ond-line hormonal therapy for prostate cancer. Ketoconazole
AF-1
AF-2
LBD CTEDBD
EPI-001
Hinge
Androgen deprivation
Medical/surgical castration
Abiraterone
VN/124-1 (TOK-001)
bicalutamide,
MDV-3100
VN/124-1 (TOK-001)DHT
Antiandrogens:
Figure 2: Therapeutic approaches to block the AR. EPI-001
interacts with the AR NTD to block AR transcriptional activity
through this domain. Inhibitors of the LBD include androgen
ablation and antiandrogens, DHT, and dihydrotestosterone.
inhibits 11-β hydroxylation, cholesterol side chain cleavage
to pregnenolone and CYP17 [36]. Two single-center trials
on the use of HDK in CRPC found PSA declines >50% in
55% (11/20) [37] and 63% (30/48) of patients [38]. A larger
phase III study of HDK therapy in 260 patients with post-
ADT metastatic PC on antiandrogen withdrawal (AAWD)
demonstrated a PSA decline >50% in 27% of patients treated
with HDK plus AAWD. Overall survival was not diﬀerent
between the treatment groups; however, those patients with
a >50% PSA decline had a median survival of 41 months
compared to 13 months for those without a PSA decline.
Time to PSA progression in PSA responders was 5.9 versus
8.6 months in AAWD alone and AAWD + HDK groups,
respectively [39]. Androstenedione, dehydroepiandrosterone
(DHEA), and dehydroepiandrosterone sulfate (DHEAS)
levels decreased with HDK therapy. However, there was no
change in testosterone level from baseline in either treatment
groups.
3.2.2. Abiraterone Acetate. Abiraterone, a highly selective
irreversible CYP17 inhibitor, was developed as a mechanism-
based steroidal inhibitor of CYP17 following observations
that nonsteroidal 3-pyridyl esters had improved selectivity
for inhibition [40]. Abiraterone has been shown to reduce
serum testosterone levels to below a detection threshold
of 1 ng/dL [41]. Promising results from clinical trials of
abiraterone acetate in CRPC patients have recently been
reported. In a phase I trial of abiraterone acetate treatment of
both ketoconazole-pretreated and ketoconazole-naı¨ve CRPC
patients [42], PSA declines of ≥50% were seen in 18
(55%) of 33 patients, including nine (47%) of 19 patients
with prior ketoconazole therapy and nine (64%) of 14
patients without prior ketoconazole therapy. Significantly,
the antitumor activity was nearly equivalent in both pop-
ulations. The activity observed in castrate, ketoconazole-
naı¨ve patients confirms that abiraterone acetate is an active
agent, whereas the activity in ketoconazole pre-treated
patients implies that a more selective and potent inhibitor of
CYP17 may be an improvement beyond ketoconazole, or an
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Figure 3: Structures of Inhibitors of CYP17.
additional sequential therapeutic option.The most common
adverse events in patients treated with abiraterone acetate
were fatigue, hypertension, headache, nausea, and diarrhea.
In addition to chemotherapy-naı¨ve patients, a multicenter
phase II study evaluated the eﬃcacy of abiraterone in patients
with docetaxel-treated CRPC [43]. All patients were treated
with 1000mg/d. Forty-seven patients were enrolled, and
treatment resulted in observed PSA declines ≥50% in 51%
(24/47) of patients at least once. Partial responses (by
RECIST criteria) were reported in 27% (8/30) patients
with measurable disease. Decreases in circulating tumor cell
(CTC) counts were also observed [43].
Two phase III clinical trials of abiraterone acetate are now
in progress. The first of these trials is designed to evaluate
abiraterone + prednisone against a placebo + prednisone in
patients with progressive CRPC after docetaxel chemother-
apy. This trial has an estimated study completion date of
June 2011 [44]. The second study will evaluate abiraterone +
prednisone against a placebo + prednisone in CRPC patients
prior to chemotherapy. The estimated study completion date
is in 2014. Both trials list prior ketoconazole treatment in
their exclusion criteria. Abiraterone was recently approved by
US Food and Drug Administration (FDA) in April 2011.
3.2.3. VN/124-1 (TOK-001). VN/124-1 was rationally de-
signed as an inhibitor of androgen biosynthesis via inhibition
of CYP17. Utilizing intact CYP17 expressing Escherichia coli,
VN/124-1 was shown to be a potent inhibitor of the enzyme
with an IC50 value of 300 nM compared to abiraterone which
had an IC50 value of 800 nM. The high eﬃcacy of VN/124-1
in several prostate cancer models is believed to arise from its
ability to downregulate the AR as well as competitively block
androgen binding. In competitive binding studies against the
synthetic androgen [3H] R1881, VN/124-1 was equipotent
to bicalutamide in LNCaP cells. Transcriptional activation
assays showed VN/124-1 to be a pure AR antagonist of the
wild-type AR and the T877A mutation found in LNCaP
cells [45, 46]. VN/124-1 inhibited the growth of CRPCs,
which had increased AR and were no longer sensitive to
bicalutamide [47].
VN/124-1 (0.13mmol/kg twice daily) caused a 93.8%
reduction (P = 0.00065) in the mean final LAPC-4 xenograft
volume compared with controls. In another antitumor
eﬃcacy study, treatment of VN/124-1 (0.13mmol twice
daily) was very eﬀective in preventing the formation of
LAPC4 tumors. VN/124-1 (0.13mmol/kg twice daily) and
VN/124-1 (0.13mmol/kg twice daily) + castration induced
regression of LAPC4 tumor xenografts by 26.55 and 60.67%,
respectively [46]. This impressive preclinical data led to
further clinical development of VN/124-1 by Tokai Pharma-
ceutical Cambridge, Mass. Tokai Pharmaceuticals initiated
ARMOR1 (Androgen Receptor Modulation Optimized for
Response 1) phase 1/2 trials in castrate-resistant prostate
cancer patients on November 5, 2009 [48]. The results of
this clinical trial are awaited. The study is expected to be
completed by July 2012.
3.3. AR Antagonists. There is ample evidence in the literature
that prostate cancer growth can be inhibited by blocking
the AR. AR antagonists compete with dihydrotestosterone
(DHT) for binding to the AR and thus block AR signaling.
Despite the significant reduction in circulating testosterone,
castration does not aﬀect adrenal androgen production.
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Therefore, antiandrogens were introduced to directly pre-
vent the binding of testosterone to the AR. Antiandrogens
competitively inhibit ligand binding to the AR and may also
prevent ligand-independent AR activation through various
pathways, such as inhibiting the recruitment of coactivators
or activating corepressors [49]. Antiandrogens are classi-
fied as steroidal or nonsteroidal based on their respective
chemical structures [50]. Themajor antiandrogens in clinical
use worldwide are the nonsteroidal bicalutamide, flutamide
and nilutamide and the steroidal cyproterone acetate (CPA)
(Figure 4). Bicalutamide is the most extensively studied
nonsteroidal antiandrogen [51]. Lowered percentages of hot
flashes as compared with castration have been reported
with bicalutamide, flutamide and CPA treatment. Patients
treated with bicalutamide have reported better preservation
of sexual interest compared with LHRH agonist alone [52]. It
is also important to note that a meta-analysis of randomized
trials comparing CPA and ADT with ADT alone showed a
survival decrease in the CPA group [53]. Overall, the non-
steroidal antiandrogens appear to be better tolerated than
castration [54]. Agents targeting AR that are in clinical
trials are summarized in Table 1. As monotherapy with an
AR antagonist is not yet a standard treatment for patients
with advanced or metastatic prostate cancer, it has been
combined with medical (or surgical) castration, initially in
studies conducted in the late 1980s and early 1990s (complete
androgen blockade). These clinical trials showed that the
combination of surgical or medical castration plus the
administration of an AR antagonist resulted in only a limited
improvement in disease-specific and overall survival in
patients with advanced and/or metastasized prostate cancer
compared to those who receive castration only [55].
Following the evidence that AR expression is increased
in CRPC, the diarylthiohydantoin MDV3100 (Figure 4) was
developed as a second-generation antiandrogen capable of
sustained AR antagonism under conditions of AR over-ex-
pression. In preclinical evaluation, MDV3100 was shown
to bind to the AR with a five- to eightfold higher aﬃnity
than bicalutamide [18, 56]. In a phase I/II study in CRPC,
antitumor activity of MDV3100 was assessed by time on
treatment, PSA, soft tissue and osseous disease and circu-
lating tumor cells (CTC). Doses of up to 600mg/day were
investigated. Out of 114 patients treated with 30–360 mg/day
and followed for over 12 weeks, 65 were chemotherapy-naı¨ve
and 49 were post chemotherapy. At 12 weeks, reduced PSA
levels were seen in both groups, with a 57% (37/65) decline
in the naı¨ve group and 45% (22/49) in the postchemotherapy
patients [18, 57]. No progression was noted in 74% (35/47)
of patients with evaluable soft-tissue legions and 62% (50/81)
of patients with bone lesions. Dose-limiting toxicity was
observed at 600mg/day. Fatigue was noted at 360 and
480mg/day. Hence, the dose was reduced. At concentrations
of 60, 150, and 240mg/day, MDV3100 was well tolerated and
no serious adverse events related to the drug were reported.
Of the 73 patients, 63 had available CTC counts. A total
of 85% of those with favorable pretreatment CTC counts
maintained favorable posttreatment CTC counts, and 58% of
patients treated at 240mg/day converted from unfavorable to
favorable, post-treatment. Bone scans revealed stable disease
in 29% (6/21) patients with osseous disease on 240mg/day. A
half-life of 1 week was established, and the current reported
data suggest a dose-response trend. Ultimately, 240mg/day
was selected for the phase III trials, and the results are much
anticipated.
Although castration and antiandrogens are very eﬀective
strategies, it is well known that PC eventually acquires
resistance. The possible mechanisms of the resistance include
amplification or overexpression of AR; gain-of-function mu-
tations allowing AR to be activated by steroids or antian-
drogens, ligand-independent activation by growth factors,
cytokines, or kinases; intracrine signaling by increased in-
tratumoral androgens; overexpression of AR coactivators;
and/or expression of constitutively active splice variants of
AR that lacks LBD may be expressed solely or in mixed pop-
ulations with full-length receptor to form a heterodimer [58–
60]. Although, various spliced variants of AR is reported,
Sawyer’s group showed that the expression of the spliced
variants of the AR are controlled by full-length AR [61].
Clearly, more studies are required to unravel the impact
of spliced variants in the development and progression of
CRPC.
For PC that has progressed to a CRPC phenotype, novel
strategies of AR inhibition could be based on knowledge re-
garding the mechanisms of AR activation in this phase of
the disease. Several studies have implicated the AR NTD as
a key mediator of ligand-independent AR activity in PC cells
[62–65]. Quayle et al. showed that a decoy molecule repre-
senting the AR NTD inhibited tumor incidence, growth, and
hormonal progression in an LNCaP xenograft model of PC
[65]. Moreover, intratumor injection of lentivirus expressing
the AR NTD decoy fragment inhibited the growth of
established LNCaP xenografts. Although preclinical studies
about the decoy NTD are impressive, future improvements
will rely on more precise modes of inhibition, for example,
targeting specific NTD transcriptional activation domains
with combinations of smaller peptide decoys or drug-like
small molecules. These types of approaches would be greatly
facilitated by structural knowledge of the entire AR protein.
Decoy AR1−558 inhibits full-length AR and blocks both
androgen-dependent and CRPC tumor growth, most likely
by a mechanism of mopping up essential proteins required
for transcriptional activity [65]. Development of shorter
decoy peptides (∼100 amino acids in length) to the AR
NTD that retain specificity for AR and still have antitumor
activity has been diﬃcult due to multiple factors, including
peptide lability and the possible requirement of multiple,
nonlinear regions of the AR NTD necessary for protein-
protein interactions. Consistent with inhibiting AR activity,
a small molecule inhibitor of AR NTD, EPI-001 (Figure 5)
blocks AR-dependent proliferation in human prostate cancer
cells that express AR and has no eﬀect on the proliferation of
cells that do not express functional AR or do not rely on the
AR for growth and survival [66].
Intravenous injection of EPI-001 significantly reduced
the weight of benign prostates from noncastrated mature
mice compared with control-treated animals [66]. EPI-001
also blocked the growth of prostate cancer xenografts in
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Figure 4: Structures of currently used antiandrogens and clinical candidate MDV3100.
Table 1: Agents targeting AR in clinical development for CRPC.
Drug Mechanism of action Patient characteristics
Phase of
development
Clinical trial
registration number
MDV-3100 AR antagonist Chemotherapy-treated Phase III NCT00974311
Chemotherapy-naı¨ve Phase III NCT01212991
ARN-509 AR antagonist ND Phase I-II NCT01171898
AZD3514 AR antagonist ND Phase I-II NCT01162395
Abiraterone acetate CYP 17 inhibitor Chemotherapy-treated Phase III NCT00638690
Chemotherapy-naı¨ve Phase III NCT00887198
Orteronel (TAK-700) CYP 17 inhibitor Chemotherapy-treated Phase III NCT01193257
VN/124-1 (TOK-001) AR downregulating agent, CYP 17
inhibitor, and AR antagonist
ND Phase I-II NCT00959959
ND: not defined.
HO O O
Cl
OH
OH
EPI-001
Figure 5: Structure of EPI-001.
the presence of androgen (noncastrated mature male mice)
and, most importantly, caused tumor regression of CRPC.
EPI-001 had no eﬀect on PC3 human prostate cancer xen-
ografts that are insensitive to androgen and do not express
functional AR indicating that its action is specific for AR
proficient cells [66].
The aforementioned antiandrogens can have synergistic
or additive eﬀects if combined with other antiandrogens or
with transcriptional modulators.
4. Epigenetic Regulators of
AR-Mediated Signaling
To regulate transcription, the receptors bind to specific
hormone response elements of target genes and exhibit
crosstalk with other transcription factors through protein-
protein interactions. Several coregulatory proteins recog-
nized by diﬀerent functional domains of the AR (the N-
terminal transactivation region, the central DNA-binding
domain (DBD), and the C-terminal ligand-binding domain)
mediate transactivation and transrepression functions of AR
and other nuclear receptors [67]. The mechanisms by which
steroid receptors compartmentalize in the nuclei and find
their specific binding motifs, hormone response elements,
from a vast number of base pairs of chromosomal DNA have
remained elusive.
Recent work indicates that epigenetic enzymes are im-
portant coactivators of AR andmay represent targets to aﬀect
AR function or stability, thus providing new therapeutic
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opportunities to overcome mechanisms of resistance and
to target AR with nonhormonal therapies. Epigenetics is
defined as the study of changes produced in gene expression
caused by mechanisms other than changes in the underlying
DNA sequence [68]. Among the diﬀerent types of epigenetic
changes, the most important are DNA methylation and
histone modifications, both of which have been shown to be
important for cancer progression [68]. A histone octamer,
composed of two copies of histone H2A, H2B, H3, and
H4, is wrapped by approximately 146 base pairs of DNA
to form the core particle of a nucleosome, the fundamental
structural unit of eukaryotic chromatin [69]. The N-terminal
tails of histones extend from the nucleosome core, providing
sites for posttranslational modifications such as acetylation,
methylation, ubiquitination, and phosphorylation. Such
modifications aﬀect chromatin structure and gene tran-
scription [70]. Histone lysine acetylation generally activates
gene transcription, whereas lysine methylation can have
diﬀerent eﬀects depending on the position and status of
methylation. Methylation of Lys4, Lys36, or Lys79 on histone
H3 usually results in transcriptional activation, whereas
methylation of Lys9 or Lys27 on histone H3 or Lys20 on
histone H4 is usually linked to transcriptional inhibition.
On a general note, methylation inhibits gene transcription
[68]. The homologues of histone-modifying enzymes, such
as HDAC6, may act to deacetylate nonhistone substrates
such as the chaperone protein HSP90, which leads to
enhanced protein stability of client proteins including AR [9–
11, 71]. The balance between repressive and active histone
modifications (also known as the histone code) ultimately
determines whether a gene will be actively transcribed or
repressed.
4.1. Histone Deacetylases (HDAC). HDACs catalyze the dea-
cetylation of the acetylated lysine residues of histones and
nonhistone proteins and are involved in various funda-
mental life phenomena, such as gene expression and cell
cycle progression. To date, eighteen HDAC family members
(HDAC1—11 and SIRT1—7) have been identified. They are
grouped into four classes based on function and homology
to their yeast counterparts: class I includes HDAC1, 2, 3, and
8; class II includes HDAC4, 5, 6, 7, 9, and 10; class III includes
Sirt1-7 class IV includes HDAC11 [72]. The functions of the
HDAC isoforms are not yet fully understood. Some of the
HDAC isoforms have been suggested to be associated with
various disease states, including cardiac diseases and cancer
[73].
Some HDACs deacetylate nonhistone substrates. More
than 50 nonhistone HDAC substrates have been identified
thus far, including key transcription factors such as p53,
E2F, alpha-tubulin, and the chaperone protein HSP90 [73].
To sum up, HDACs regulate gene expression by modifying
histone and nonhistone proteins. HDACs are upregulated
in many cancers. Halkidou et al. showed that HDAC1 is
overexpressed in prostate cancer [74]. Another type of
HDAC-HDAC6 is an important protein for AR activity. It is
described below.
4.1.1. HDAC6. Histone deacetylase 6 (HDAC6) is a cyto-
plasmic enzyme that regulates many important biological
processes, including cell migration, immune synapse forma-
tion, and the degradation of misfolded proteins. HDAC6
deacetylates tubulin, Hsp90, and cortactin and forms com-
plexes with other partner proteins. It is the only HDAC
that possesses two functional deacetylase domains and a zinc
finger (ZnF) motif [75, 76]. In vivo, the enzymatic activity
of HDAC6 is exerted on tubulin, heat shock protein 90
(Hsp90), and cortactin substrates; however, in vitro, HDAC6
is also able to deacetylate histones [75–77]. The Zn2+ chelator
trichostatin A (TSA) reversibly inhibits HDAC6 deacetylase
activity [77, 78].
AR requires peculiar cellular machinery to achieve the
appropriate conformation for binding ligand [79]. Heat
shock protein 90 (Hsp90) plays a central role in the for-
mation of a multichaperone complex essential for stabilizing
steroid receptors in a conformation receptive to ligand
[80, 81]. Hsp90 regulates the AR protein half-life by
forming conformation-dependent higher-order chaperone
complexes. Hsp90 inhibition prevents the ligand-dependent
nuclear translocation of AR, suggesting a role for Hsp90 in
the nuclear import of AR [82].
HDAC6 reversibly deacetylates Hsp90, modulating
Hsp90 regulation of nuclear receptors, including AR and
glucocorticoid receptor (GR) [10, 83, 84]. Inactivation of
HDAC6 results in the accumulation of acetylated Hsp90,
which no longer forms a stable complex with GR, lead-
ing to defective GR ligand binding, nuclear translocation,
and transactivation [10]. These findings strongly implicate
HDAC6-mediated acetylation/deacetylation of Hsp90 as a
potential mechanism regulating steroid hormone signaling.
AR forms chaperone complexes with Hsp90 [85]. Recently,
it was reported that HDAC6 is required for stabilization of
AR protein [86], Ai et al. demonstrated that inactivation of
HDAC6 inhibited AR nuclear localization and subsequent
transactivation in PC and mouse embryonic fibroblast
(MEF) cells [87]. Reexpressing HDAC6 or a deacetylation-
mimic Hsp90 mutant alleviated the inhibition. Furthermore,
HDAC6 knockdown also inhibited the establishment of
C4-2 xenograft tumors in castrated, but not testis-intact,
nude mice. These findings together provide evidence for
an important role for HDAC6 in AR hypersensitivity and
nuclear localization in castration-resistant PC cells, and thus
HDAC6 is a very important target which can be exploited in
CRPC treatment.
4.1.2. HDAC Inhibitors. To date, SAHA and romidepsin are
the only FDA-approved HDAC inhibitors (Figure 6) [88, 89].
On a general note, HDAC inhibitors cause histone hy-
peracetylation, activating many genes, which leads to growth
inhibition, diﬀerentiation, or apoptosis [73]. Clinical out-
come with HDAC inhibitors to fight prostate cancer has
yielded disappointing results. However, HDAC inhibitor
therapy in prostate cancer still holds great promise due
to recent developments. A recent report showed that class
I HDACs are essential coactivators of AR (Table 2) [90].
Two widely used HDAC inhibitors, SAHA and LBH589,
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Figure 6: FDA-approved HDAC inhibitors.
block transcriptional activation of many AR targets, such as
TMPRSS2-ERG [90]. This eﬀect was recapitulated by siRNA
to HDAC1, and, to a lesser extent, by siRNA to HDAC3
[90]. Further, Welsbie et al. also showed that these HDAC
inhibitors do not block AR recruitment to its targets, rather,
they suppress AR target gene activation by blocking the re-
cruitment of AR coactivators and RNA polymerase II [90].
These findings highlight the need for more specific and less
toxic HDAC inhibitors in the treatment of PC.
Some of the HDAC inhibitors serve the dual functions
of disrupting AR signaling and reducing AR protein lev-
els in the cell. Multiple reports have shown that HDAC
inhibitors suppress AR expression [11, 90–92]. Gibbs et al.
reported that sulforaphane—an important constituent in
cruciferous vegetarian diet, enhances HSP90 acetylation
through HDAC6 inactivation, which leads to disruption of
AR binding to HSP90, eventual AR degradation, and reduced
expression of AR target genes [93]. Unlike other compounds
with HDAC inhibitory function, sulforaphane treatment led
to reduced AR binding to its target gene AREs [93]. To
sum up, HDAC inhibitors, including compounds such as
sulforaphane with eﬀects on HDAC6, inhibit prostate cancer
cell growth, which is at least partially explained by eﬀects on
AR signaling. Isoform-selective HDAC inhibitors are of great
interest as candidate therapeutic agents with few side eﬀects.
Kang et al. [95] showed that transcriptional activation
by AR is accompanied by a cascade of distinct covalent
histone modifications. Korkmaz et al. [96] studied the role
of histone acetylation on AR function. Using three inde-
pendent HDAC inhibitors: depsipeptide (FR901228), sodi-
um butyrate (NaB), and TSA, they found that inhibition
of HDAC activity caused significantly increase in the tran-
scription ability of AR in the LNCaP cell. They found dose-
dependent eﬀects of NaB and depsipeptide on AR activity:
low doses caused increase in levels of PSA mRNA, whereas
high doses of NaB completely inhibited PSA expression. This
implies that HDAC inhibitors repress both AR expression
and AR-dependent expression of PSA in a dose-dependent
manner [96, 97]. Another mechanism of AR suppression
by HDAC inhibitors was shown by Welsbie et al. [90].
HDAC inhibitors, vorinostat (SAHA), and LBH589 block
AR activity through suppression of the coactivator/RNA
polymerase II complex assembly after binding of AR to the
promoters of target genes. Rokhlin et al. [91] found that TSA
sharply reduced AR gene expression after 24 hours treatment,
with partial recovery after 48 hours and returned to normal
levels after 72 hours later.
4.2. SUMO-1 (Small Ubiquitin-Like Modifier-1). The
SUMO-1 modification (sumoylation) pathway resembles
that of ubiquitin conjugation, but the enzymes involved in
the two processes are distinct [98]. SUMO-1 (also known
as sentrin, GMP1, PIC1, and Ubl1, or in yeast as Smt3) is
activated for conjugation by E1 enzymes and subsequently
transferred to the E2-conjugating enzyme Ubc9 [99].
Sumoylation is reversible [100]. The sumoylation appears
to play multiple roles, including (i) protein targeting, (ii)
protein stabilization, and (iii) transcriptional activation.
Poukka et al. showed that AR is covalently modified by
SUMO-1. They identified that sumoylation sites are present
in the N-terminal domain of AR, and they further showed
that the SUMO-1 modification in certain contexts indeed
inhibits the activity of AR [26].
4.3. N-CoR and SMRT. N-CoR and SMRT are well char-
acterized corepressors. Given the evidence that SMRT and
NCoR form complexes with HDAC3 [76, 101, 102], these
corepressors could have an additive eﬀect on the inhibition of
transcription and histone acetylation. However, despite the
roles of SMRT and NCoR in regulating the transcriptional
activity of several nuclear receptors, the significance of SMRT
and/or NCoR on AR transcriptional activity is less clear. Both
SMRT and NCoR proteins interact with AR. The AR specific
domain binds to the PSA promoter or to various AREs of
AR target genes [97, 103]. Trtkova´ et al. analyzed the binding
of AR-SMRT complex to PSA promoter and/or binding AR
alone to PSA promoter using various NaB concentrations.
The ChIP analysis coupled with qPCR of LNCaP and C4-2
cells demonstrated that NaB promoted the formation of the
AR-SMRT complex [104]. In summary, N-CoR and SMRT
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Table 2: List of HDACs that play a role in AR signaling.
Enzymes Substrates Modulation of AR signaling References
HDAC1 Histones, p53, Smad7, Stat3, and so forth
Facilitates AR-dependent transcription;
mechanism not fully clarified
[90, 94]
HDAC3 Histones, Smad7, Stat3, SRY, NFκB, and so forth
Facilitates AR-dependent transcription;
mechanism not fully clarified
[90, 94]
HDAC6 Alpha-tubulin, HSP90
Deacetylates HSP90 which enhances chaperoning
of AR protein
[9, 10, 93]
also provide additional epigenetic targets which need to be
explored.
4.4. Histone Methylation and Demethylases. Histone methy-
lation was originally thought to be a stable, irreversible
mark as only histone methyltransferases had been identified
with no known data about demethylases. However, the dis-
covery of the first histone demethylase LSD1 (lysine-spe-
cific demethylase 1) confirmed that histone methylation is
reversible [105, 106]. The status of histone lysinemethylation
has been shown to be important for AR signaling, and several
histone demethylase proteins are upregulated in prostate
cancer. These include LSD1 and the Jumonji class of proteins
[107–109]. While the transcriptional targets of these proteins
are largely unknown, these proteins complex with AR and
facilitate its activation of downstream signaling pathways.
While LSD1 may demethylate the active dimethyl lysine
4 (2MK4) mark on histone H3, which leads to reduced
gene expression of AR-regulated genes, several reports show
that LSD1 binds to AREs, the site where AR binds to
the DNA and facilitates demethylation of the repressive
mono-(1MK9) and dimethyl lysine 9 (2MK9) marks on
histone H3 upon recruitment of ligand-bound AR, which
results in transcriptional derepression [107, 108]. Given
the importance of these enzymes in the activation of AR
target genes, inhibition of these enzymes may be a rational,
nonhormonal strategy to disrupt AR signaling. MAOIs
(monoamine oxidase inhibitors) and polyamine analogues
are some of the currently known compounds that inhibit
LSD1 activity [107]. These agents need to be further eval-
uated for their potential to treat prostate cancer.
5. Conclusions
Androgen deprivation has been the major therapy for
prostate cancer for 7 decades. After a few months of ADT,
PC progresses despite castrate serum levels of testosterone.
We now have a greater understanding of the mechanisms of
sustained AR signaling in these CRPCs that have progressed
despite androgen deprivation. Cofactors such as HDACs,
SUMO-1, N-CoR, and SMRT provide additional level of
control of AR signaling. Upregulation of cofactors such as
HDACs that facilitate AR target gene activation is an impor-
tant event in the development of CRPC. Whether targeting
histone deacetylases and other AR coactivators or AR protein
stability will be safe and eﬃcacious remains unknown, but
their preclinical data holds a great promise. Most of the
currently developed therapies targeting AR signaling aim
at the LBD of AR. However, with the knowledge that AR
NTD can function independent of AR LBD, newer therapies
such as EPI-001 and decoy AR NTD are being developed
to target AR NTD. All of these antiandrogens and HDAC
inhibitors may show synergistic/additive activities when used
in combination. There is a great interest to combine these
agents to eﬀectively treat CRPC.
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